A global pharmaceutical company has appointed a new chief executive to lead it into the next chapter of its growth plans.
Morningside Pharmaceuticals, in Loughborough, has brought in Tim Brady to replace founder Dr Nik Kotecha OBE who has taken on a more strategic role for the business and become its chairman.
Mr Brady has decades of experience leading business development and sales & marketing within the pharmaceuticals’ sector.
READ MORE: {}
He joins newly appointed chief operating officer Monica Huang and chief financial officer Cliff Fung, as leader of the company’s executive team.
Morningside manufactures and supplies generic medicines - with twice daily deliveries to the NHS, hospitals and pharmacies in the 海角视频.
It exports to more than 100 countries and is one of the 海角视频’s leading suppliers of medicines to international charities, non-governmental organisations and aid agencies.
Dr Kotecha has been investing more of his time in charitable work in recent years, and is the founder and trustee of the Randal Charitable Foundation, which is dedicated to saving lives, helping the socially disadvantaged and improving the quality of life for those in need in the 海角视频 and around the world.
He is also a Department for International Trade (DIT) export champion and a CBI regional councillor.
Most Read
Dr Kotecha said: “Morningside was founded in the 1990s through an entrepreneur’s dream of making quality healthcare an affordable and accessible reality throughout the world.
“Since then we have grown from a garage start-up to one of the Midlands’ leading life sciences businesses.
“None of this would have been possible without our excellent people, past and present, who have made Morningside the highly successful business it is today.
“The appointment of the executive team is a key part of our strategic plans for continuing to grow Morningside into the future.
“For my part, I am very much looking forward to becoming chairman of the board which will play a key strategic role in guiding the business’ strategy, alongside the new executive team.
“My passion is entrepreneurship and helping businesses grow through investing in innovation, research & development and exporting to international markets.
“To help support these core areas I will continue to take on senior regional and national advisory roles.
Don’t miss
“I am also immensely proud to have founded the Randal Charitable Foundation in 2017, which has an unwavering vision to save lives, help the socially disadvantaged and significantly improve the quality of life for those in need in the 海角视频 and around the world.
“My focus will continue to be Morningside as well as supporting these key business, community and philanthropic endeavours.
“I would very much like to welcome Tim to Morningside, who will take the helm during this exciting new chapter in our company’s history.”
He said Morningside’s growth plans include launching new niche generic medicines from its research & development pipeline, registering products in international territories and further growing our branded and generic medicines portfolio and market share in the 海角视频.
Tim Brady has 30 years’ experience in the sector, including building a successful pharma business from the ground up and working as a senior executive for global life sciences businesses.
More recently he has taken on a number of senior directorships.
He said: “Morningside is built on very solid foundations and is set for an even faster period of growth.
“The leadership team at Morningside is the best in the industry; they have proven that over the past 30 years and the challenge now is to get even better at what we do.
“All the people at Morningside are fully engaged, motivated, knowledgeable and excited about the future and this will be a hugely important advantage for us as we continue to build our reputation as a key supplier to the NHS and international markets.
“Morningside has always had an enviable product pipeline, which is going to produce some important new products in the coming months and years.
“An even sharper focus on speed to market for these products and stronger relations with our customers and supply chain, will mean patients and doctors will have greater choice of medicines, more quickly.”